These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17047615)

  • 1. [Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia].
    Susekov AV; Zubareva Mi; Tripoten' MI; RozhkovaT A ; Pogorelova OA; Balakhonova TV; Masenko VP; Kukharchuk VV
    Kardiologiia; 2006; 46(9):4-10. PubMed ID: 17047615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
    Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
    Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
    Samoĭlenko EIu; Naumov VG; Tvorogova MG; Ezhov MV; Sergienko IV; Kukharchuk VV
    Kardiologiia; 2007; 47(2):4-8. PubMed ID: 17495815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall].
    Susekov AV; Rozhkova TA; Tripoten' MI; Pogorelova OA; Kulev BD; Balakhonova TV; Zubareva MIu; Masenko VP; Rogozova AN; Kukharchuk VV
    Kardiologiia; 2007; 47(2):25-30. PubMed ID: 17495819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis].
    Tutunov VS; Popkova TV; Novikova DS; Nasonov EL; Kukhrchuk VV
    Kardiologiia; 2008; 48(9):4-8. PubMed ID: 18991814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
    Pokrovskaia EV; Vaulin NA; Gratsianskiĭ NA; Averkov OV; Deev AD
    Kardiologiia; 2003; 43(1):7-18. PubMed ID: 12891281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
    Kuznetsova MA; Vaulin NA; Masenko VP; Gratsianskiĭ NA
    Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
    Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
    Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
    Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
    Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine.
    Xu DY; Shu J; Huang QY; Wasti B; Chen C; Liu L; Zhao SP
    Atherosclerosis; 2010 Jul; 211(1):237-41. PubMed ID: 20189174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.